The most robust strategy for therapeutic antibody discovery continues to be through the use of immunized animals and the ability to isolate, interrogate, and/or immortalize immune B-cells. However, capturing the full repertoire of an immunized animal is a challenge that has come to the forefront, particularly as more difficult therapeutic targets have become the industry focus. Various technologies exist for immortalizing and interrogating immune B-cells, though each strategy presents distinct advantages and disadvantages. To this end, Antibody Solutions and Single Cell Technology (SCT) have launched a partnership to integrate SCT’s pioneering single B-cell analysis technology with Antibody Solutions’ comprehensive antibody discovery platform.
Antibody Solutions’ service platform features elements critical for successful antibody discovery, including antigen design and validation, immune B-cell generation and isolation from conventional and human transgenic rodents, highthroughput cell screening for detecting target specific antibodies, Hybridoma LibrariesTM, and recombinant expression of candidate antibodies. Single Cell Technology’s pioneering AbTHENEUMTM technology allows for the phenotypic screening of secreted antibodies from individual B-cells and the correct pairing of cognate VH and VL sequences from each individual cell via NGS. By the addition of this new technology to Antibody Solutions’ discovery platform, the repertoire of immunized animals can be interrogated more comprehensively than if a single approach were pursued.
We present a comprehensive platform for therapeutic antibody discovery using both Hybridoma LibraryTM and AbTHENEUMTM Single B-cell Analysis. The Hybridoma LibraryTM enables the isolation of rare Ag-specific B Cells. AbTHENEUMTM Single B-cell analysis allows for phenotypic screening of thousands of primary B cells in primary lymphoid tissue and paired VH / VL sequences by NGS. Multiple strategies for obtaining Ag-specific Bcells and different methods of identification has the potential to increase the diversity and size of the the pool of candidate therapeutic antibodies.
Download this poster
We invite you to download our poster that details this research study, including our antibody discovery strategy as well as the Spike protein reagents, screening assay formats, and more that we utilized.
Joshua Lowitz, John S. Kenney, Michael Trang, Glen Lin, Jennifer Somera, Leonel Santibanez-Vargas, Catherine Vo, Allison Schulkins, Joy Tang, Jim Bowlby, Rich Jorgensen and Chun-Nan Chen, Antibody Solutions, Sunnyvale, CA, USA and Single Cell Technology, San Jose, CA USA